# A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours

> **NCT04914117** · PHASE1 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 7 (actual)

## Conditions studied

- Unresectable Solid Tumor
- Metastatic Solid Tumor
- Locally Advanced Solid Tumor

## Interventions

- **DRUG:** RC118 for injection

## Key facts

- **NCT ID:** NCT04914117
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-29
- **Primary completion:** 2022-11-15
- **Final completion:** 2023-03-11
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04914117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04914117, "A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04914117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*